Join Growin Stock Community!
Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • P/E Ratio
  • P/S Ratio
  • P/B Ratio
  • EV/EBITDA
  • EV/Sales
ev-to-sales-chart

RXRX EV/Sales

EV/Sales

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for RXRX's EV/Sales ratio in Q1'26 stands at 161.13, reflecting a notable rebound from the previous quarter's low of 37.10 in Q4'25, though it remains below the series peak of 556.54 observed in Q4'24. Over the period from Q2'23 to Q1'26, the EV/Sales ratio has exhibited high volatility with no consistent upward or downward trend, fluctuating between a low of 37.10 in Q4'25 and a high of 556.54 in Q4'24; significant spikes occurred in Q4'23 (258.41), Q4'24 (556.54), and Q3'25 (386.82), interspersed with declines to 63.62 in Q3'24 and 75.46 in Q3'23, suggesting market-driven swings in valuation multiples rather than steady growth or contraction. This pattern underscores the speculative nature of RXRX's enterprise value relative to sales in the biotech sector.